0000000000042918

AUTHOR

Helmut J. Wieler

showing 11 related works from this author

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

2020

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study is to determine the optimum time for performing these PET/CT scans in a large cohort of patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve (ROC) generated by plottin…

Biochemical recurrenceCancer Researchmedicine.medical_treatment68Gallium-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine<sup>68</sup>gallium-psma pet/ctprostate-specific-antigenPSA kinetics thresholdsbiochemical recurrenceMedicineoptimal cutoff levelPET-CTPsa kineticsbusiness.industryProstatectomylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensprostate cancermedicine.diseaseRadiation therapyProstate-specific antigenOncology030220 oncology & carcinogenesisRecurrent prostate cancerbusinessNuclear medicineCancers
researchProduct

The significance of FNAC in diagnosing differentiated thyroid cancer and the discrepancy between theory and practice - a multi-centre study.

2020

 After non-invasive diagnostic modalities high risk thyroid nodules are investigated with fine needle aspiration cytology in order to find the right surgical strategy for suspected malignancies. Despite the clear recommendation by the European and the American associations (ETA, ATA) its clinical value is doubted and its importance in clinical practice not fully clarified. A multicentric study of 119 patients with differentiated thyroid cancer operated on in 24 surgical departments was conducted. The aim was not only to evaluate the use of FNAC as a diagnostic tool, but also to investigate its diagnostic validity and compare it with that of other, non-invasive diagnostic methods. FNAC was u…

Thyroid nodulesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentBiopsy Fine-NeedleScintigraphyCohort StudiesDiagnosis DifferentialYoung AdultBiopsymedicineHumansRadiology Nuclear Medicine and imagingThyroid Neoplasmsskin and connective tissue diseasesThyroid cancerAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasebody regionsLymphadenectomyFemaleRadiologyUltrasonographybusinessCohort studyNuklearmedizin. Nuclear medicine
researchProduct

The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.

2018

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an exce…

MaleUrology030232 urology & nephrologyComputed tomographyGallium Radioisotopesurologic and male genital diseasesMultimodal ImagingManagement of prostate cancer03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographymedicineOrganometallic CompoundsHumansGallium IsotopesMembrane antigenSalvage TherapyPET-CTMembrane Glycoproteinsmedicine.diagnostic_testbusiness.industry68ga psmaProstatic NeoplasmsMagnetic resonance imagingProstate carcinomaProstate-Specific AntigenMagnetic Resonance ImagingPositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyNeoplasm Recurrence LocalRadiopharmaceuticalsbusinessNuclear medicineUrology
researchProduct

Tc-99m HMPAO Cerebral Scintigraphy A Reliable, Noninvaslve Method for Determination of Brain Death

1993

To determine the usefulness of cerebral blood flow imaging for the diagnosis of brain death, 4 female and 12 male patients, aged 19 to 69 years and suffering from various intracranial lesions, were studied. In addition to neurologic examination, electroencephalographic recording, and cerebral angiography, tomographic brain scintigraphy was performed using a SPECT system with a LEAP collimator after the intravenous administration of 555 MBq Tc-99m HMPAO. The radioisotopic scanning procedure revealed no intracranial perfusion in 14 of the 16 patients. Only minimal cerebellar blood flow was seen in one patient. In another, residual right-sided supratentorial flow was initially present but abse…

AdultMaleBrain DeathHemodynamicsScintigraphyTechnetium Tc 99m ExametazimeOximesmedicineHumansRadiology Nuclear Medicine and imagingRadionuclide ImagingAgedmedicine.diagnostic_testbusiness.industryBrainOrganotechnetium CompoundsGeneral MedicineBlood flowMiddle AgedCerebral blood flowCerebrovascular CirculationAngiographyTechnetium Tc 99m ExametazimeFemaleNuclear medicinebusinessPerfusionCerebral angiographyClinical Nuclear Medicine
researchProduct

Reply: “The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer”

2019

PET-CTmedicine.diagnostic_testbusiness.industryUrology68ga psmaMagnetic resonance imagingPet imagingManagement of prostate cancerPositron emission tomographymedicineHaloNuclear medicinebusinessScatter correctionUrology
researchProduct

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Ge…

2021

A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany’s vaccination campaign started on December 2020, vaccination prioritization was initially carried out starting with older population groups. Side effect rates in 1065 individuals who had received the first dose of the messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- and gender-graded data analysis showed clear age and gender differences with regard to vaccine-related adverse effects. In 77% of all in…

Pediatricsmedicine.medical_specialtySide effectCoronavirus disease 2019 (COVID-19)COVID-19 vaccinationImmunologyage- and sex-graded data evaluationArticleHerd immunityImmunityDrug DiscoveryPandemicmedicinePharmacology (medical)Adverse effectPharmacologyvaccination strategymRNA vaccine BNT162b2business.industryRVaccinationInfectious DiseasesPopulation studyMedicinebusinessvaccination side effectsVaccines
researchProduct

Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of …

2020

Gallium-68 (Ga) prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography is a highly promising method for imaging primary and recurrent prostate cancer. These dual-modality imaging technologies enable whole-body functional and anatomical evaluation in a single session. This study investigated the performance of Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with Ga-prostate-specific-membrane-antig…

Biochemical recurrenceMalemedicine.medical_specialtyEpidemiologyHealth Toxicology and MutagenesisGallium RadioisotopesRisk Assessment68Ga-PSMA-11Cohort StudiesProstate cancerPositron Emission Tomography Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingRadiation treatment planningPathologicalEdetic AcidGallium IsotopesPositron Emission Tomography-Computed TomographyNeoplasm StagingRetrospective Studiesbusiness.industryProstatic NeoplasmsProstate carcinomamedicine.diseaseLarge cohortTreatment OutcomeGene Expression RegulationLymphatic MetastasisRadiologyNeoplasm Recurrence LocalbusinessOligopeptidesHealth physics
researchProduct

Dual-Time Point [68Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer

2020

Routine [68Ga]Ga-PSMA-11 PET/CT (one hour post-injection) has been shown to accurately detect prostate cancer (PCa) lesions. The goal of this study is to evaluate the benefit of a dual-time point imaging modality for the staging and restaging of PCa patients. Biphasic [68Ga]Ga-PSMA-11 PET/CT of 233 patients, who underwent early and late scans (one/three hours post-injection), were retrospectively studied. Tumor uptake and biphasic lesion detection for 215 biochemically recurrent patients previously treated for localized PCa (prostatectomized patients (P-P)/irradiated patients (P-I) and 18 patients suspected of having primary PCa (P-T) were separately evaluated. Late [68Ga]Ga-PSMA-11 PET/CT …

Cancer Research[<sup>68</sup>Ga]Ga-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicinedelayed imagingmedicineLymph nodebiphasic imagingPET-CTlesion positivity rateLesion detectionbusiness.industrymedicine.diseaseprostate cancerdual-time point imaginglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTracer uptakeCt imagingPreviously treatedbusinessNuclear medicineDual time pointCancers
researchProduct

Contribution of thallium-201-SPECT to the grading of tumorous alterations of the brain

1992

Single photon emission computed tomography (SPECT) with thallium-201-chloride (201Tl) was used in 22 patients to assess the grade of malignancy of brain tumors. Low- and high-grade malignant gliomas could be well differentiated by calculating the Grade Index (GI), i.e., 201Tl uptake in the tumor area relative to a contralateral brain region. Low-grade gliomas (WHO-grade I-II) usually showed a GI of1.5. Tumors classified histologically as high-grade malignant (WHO-grade III-IV) had GI values greater than 1.42 and a mean value of 1.89. Until labelled amino-acid tracers for gamma-cameras become commercially available, thallium-201 brain-SPECT can provide an independent and complementary method…

AdenomaAdultMalemedicine.medical_specialtychemistry.chemical_elementAstrocytomaSingle-photon emission computed tomographyMalignancyDiagnosis DifferentialMeningeal NeoplasmsmedicineHumansPituitary NeoplasmsGrading (tumors)AgedNeoplasm StagingTomography Emission-Computed Single-Photonmedicine.diagnostic_testBrain Neoplasmsbusiness.industryBrainGliomaNeuroma AcousticGeneral MedicineMiddle Agedmedicine.diseaseThallium RadioisotopeschemistryPositron emission tomographyThalliumFemaleSurgeryNeurology (clinical)NeurosurgeryMeningiomabusinessNuclear medicineNeurosurgical Review
researchProduct

Diagnostic efficacy of Gallium-68-PSMA PET/CT in 565 patients with biochemical recurrence of prostate cancer

2019

OncologyBiochemical recurrencemedicine.medical_specialtyProstate cancerchemistrybusiness.industryInternal medicineMedicinechemistry.chemical_elementGalliumbusinessmedicine.diseasePsma pet ct57. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct

PSA and PSA kinetics as predictor of a positive Ga-68-PSMA-11 PET/CT scan for restaging prostate cancer

2020

Prostate cancerPET-CTPsa kineticsbusiness.industrymedicineNuclear medicinebusinessmedicine.disease58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct